Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) Upgraded at Zacks Investment Research

Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Tuesday, August 29th. The brokerage presently has a $1.25 target price on the biotechnology company’s stock. Zacks Investment Research‘s price target suggests a potential upside of 12.61% from the company’s previous close.

According to Zacks, “Bellerophon Therapeutics LLC is a biotherapeutics company. It is focused on developing products for the treatment of cardiopulmonary and cardiac diseases. The company’s product pipeline consists of INOpulse and BCM which are in different clinical stage. Bellerophon Therapeutics LLC is based in Hampton, New Jersey. “

Separately, ValuEngine downgraded Bellerophon Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, June 10th.

Bellerophon Therapeutics (NASDAQ:BLPH) traded down 5.41% during mid-day trading on Tuesday, hitting $1.05. The company had a trading volume of 296,944 shares. Bellerophon Therapeutics has a one year low of $0.43 and a one year high of $1.69. The company’s market cap is $37.29 million. The company’s 50 day moving average price is $1.18 and its 200-day moving average price is $1.33.

Bellerophon Therapeutics (NASDAQ:BLPH) last issued its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($0.12) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.03. Equities research analysts anticipate that Bellerophon Therapeutics will post ($1.12) EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This report was originally published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this report on another website, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright legislation. The legal version of this report can be read at https://stocknewstimes.com/2017/09/13/bellerophon-therapeutics-inc-blph-lifted-to-buy-at-zacks-investment-research.html.

Hedge funds and other institutional investors have recently modified their holdings of the business. Susquehanna International Group LLP bought a new stake in shares of Bellerophon Therapeutics during the 2nd quarter worth about $1,316,000. Vanguard Group Inc. boosted its stake in shares of Bellerophon Therapeutics by 52.6% during the 2nd quarter. Vanguard Group Inc. now owns 612,641 shares of the biotechnology company’s stock worth $821,000 after acquiring an additional 211,111 shares in the last quarter. Renaissance Technologies LLC boosted its stake in shares of Bellerophon Therapeutics by 99.7% during the 1st quarter. Renaissance Technologies LLC now owns 477,400 shares of the biotechnology company’s stock worth $711,000 after acquiring an additional 238,300 shares in the last quarter. Finally, Goldman Sachs Group Inc. bought a new stake in shares of Bellerophon Therapeutics during the 1st quarter worth about $125,000. Hedge funds and other institutional investors own 45.85% of the company’s stock.

About Bellerophon Therapeutics

Bellerophon Therapeutics, Inc is a clinical-stage therapeutics company. The Company is focused on developing products at the intersection of drugs and devices that address medical needs in the treatment of cardiopulmonary diseases. The Company is focused on the development of its nitric oxide therapy for patients with pulmonary hypertension (PH), using its delivery system, INOpulse, with pulmonary arterial hypertension (PAH) as the lead indication.

Get a free copy of the Zacks research report on Bellerophon Therapeutics (BLPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Bellerophon Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply